FATE Key Statistics, Chart & Performance
The current stock price of FATE is 1.05 USD. In the past month the price decreased by -3.67%. In the past year, price decreased by -28.33%.
FATE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About FATE
Company Profile
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Company Info
FATE THERAPEUTICS INC
12278 Scripps Summit Drive
San Diego CALIFORNIA 92121 US
CEO: J. Scott Wolchko
Employees: 181
Phone: 18588751803
FATE THERAPEUTICS INC / FATE FAQ
Can you describe the business of FATE THERAPEUTICS INC?
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Can you provide the latest stock price for FATE THERAPEUTICS INC?
The current stock price of FATE is 1.05 USD. The price decreased by -0.94% in the last trading session.
Does FATE stock pay dividends?
FATE does not pay a dividend.
How is the ChartMill rating for FATE THERAPEUTICS INC?
FATE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in FATE THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FATE.
What is FATE THERAPEUTICS INC worth?
FATE THERAPEUTICS INC (FATE) has a market capitalization of 121.12M USD. This makes FATE a Micro Cap stock.
What is the ownership structure of FATE THERAPEUTICS INC (FATE)?
You can find the ownership structure of FATE THERAPEUTICS INC (FATE) on the Ownership tab.
FATE Technical Analysis
FATE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FATE. FATE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FATE Financial Highlights
Over the last trailing twelve months FATE reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS increased by 20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.42% | ||
| ROE | -66.69% | ||
| Debt/Equity | 0 |
FATE Forecast & Estimates
18 analysts have analysed FATE and the average price target is 5.04 USD. This implies a price increase of 380.31% is expected in the next year compared to the current price of 1.05.
For the next year, analysts expect an EPS growth of 28.57% and a revenue growth -52.5% for FATE